Umeclidinium bromide

Feb 20, 2018

Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018

Nov 28, 2017

Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta

Nov 21, 2017

Theravance Biopharma to Present at Two Upcoming Investor Conferences

Nov 16, 2017

Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD

Oct 30, 2017

Theravance Biopharma to Report Third Quarter 2017 Financial Results on November 7, 2017

Sep 20, 2017

Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of Trelegy Ellipta Announced by GlaxoSmithKline and Innoviva

Sep 19, 2017

Theravance Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2017

Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

Sep 18, 2017

Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple)

Sep 05, 2017

Theravance Biopharma to Present at the Morgan Stanley 15th Annual Global Healthcare Conference